21 January 2021 – SCHLIEREN (Zürich – Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Karel Novy, PhD as Chief Operating Officer.
Karel joined Biognosys in 2016 and held positions of increasing responsibility in Business Development and Scientific Operations.
He graduated from the ETH Zurich in Biotechnology with a focus in synthetic biology. Karel obtained his PhD from ETH Zurich, Department of Biology, Institute of Molecular Systems Biology (group of Prof. Wollscheid) for his work on deciphering signaling networks underlying poxvirus infection and the viral replication cycle by mass spectrometry.
After his PhD, Karel moved to Melbourne (Australia) for a postdoctoral fellowship at Monash University (group of Prof. Daly) focusing on profiling signaling networks in triple-negative breast cancer by mass spectrometry.
Aside from his scientific achievements, Karel was an Olympic athlete, competing in the Sydney, Athens, and Beijing Olympics for the Swiss National Swimming team.
As Chief Operating Officer Karel is responsible for the Operations department focusing on contract research projects. In this position, he will continue to ensure Biognosys’ operational excellence as a leader in Large-Scale Proteomics, with a focus on enhanced customer service, facility extension and GxP accreditation, and further competency development in data analytics.
Karel Novy, PhD commented:
“I am looking forward to working together with our team of truly dedicated and talented scientists to ensure our customers’ satisfaction. Biognosys' operations department will continuously improve its services both by implementing new developments from Biognosys' R&D department and by finalizing the GCP and GLP compliant framework enabling the deployment of discovery proteomics in pre-clinical and clinical trials.”
Oliver Rinner, PhD stated:
“I am happy to welcome Karel as part of our executive management team. At this transition point where proteomics moves into the spotlight of the life science market, Karel, with his deep expertise in proteomics and contract research operations is ideally suited to fulfill our mission to make cutting edge proteomics technology widely available.”
Karel succeeds Claudia Escher in the COO position, who will pursue an opportunity outside proteomics. We thank Claudia for more than 10 years of service and outstanding contributions at Biognosys and wish her many successes in her future career endeavors.
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by developing the most advanced proteomics tools and making them available for pharmaceutical and biotech research and development. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression and regulation in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at www.biognosys.com
Karel Novy, PhD
Chief Operating Officer
Phone +41 (0) 44 738 20 47
Mobile +41 (0) 79 709 02 22